Related Experiment Video

Updated: Aug 10, 2026

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting
11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates

P M Wallace1, P D Senter

  • 1Bristol Myers Squibb Pharmaceutical Research Institute, Seattle, Washington.

Methods and Findings in Experimental and Clinical Pharmacology
|September 1, 1994
PubMed

Insights

Targeted monoclonal antibody-enzyme conjugates enable site-selective anticancer drug generation at solid tumors. This approach enhances drug delivery and antitumor activity compared to systemic administration, offering a promising cancer therapy strategy.

Area of Science:

  • Biotechnology
  • Oncology
  • Pharmacology

Background:

  • Anticancer drug development faces challenges in achieving site-selectivity and minimizing systemic toxicity.
  • Targeted drug delivery systems are crucial for improving therapeutic efficacy in cancer treatment.
  • Monoclonal antibody-enzyme conjugates offer a promising platform for site-specific prodrug activation.

Purpose of the Study:

  • To demonstrate the efficacy of monoclonal antibody-enzyme conjugates for site-selective anticancer drug generation at solid tumors.
  • To evaluate the antitumor activity and specificity of antibody-enzyme/prodrug combinations.
  • To explore the potential of this approach for delivering potent drugs and overcoming multidrug resistance.

Main Methods:

  • Development of monoclonal antibody-beta-lactamase conjugates for activating various anticancer prodrugs.
  • Utilizing targeted cytosine deaminase for enhanced 5-fluorouracil generation within tumors.
  • Investigating prodrugs releasing potent toxins and targeting multidrug-resistant cancer cells.

Main Results:

  • Monoclonal antibody-beta-lactamase conjugate/prodrug combinations showed superior antitumor activity compared to systemic drug administration.
  • The targeted approach demonstrated immunological specificity.
  • Targeted cytosine deaminase resulted in up to 17-fold greater drug delivery within tumors than standalone 5-fluorouracil.

Conclusions:

  • Site-selective prodrug activation using targeted antibody-enzyme conjugates is an effective strategy for cancer therapy.
  • This method significantly enhances drug concentration at the tumor site and improves therapeutic outcomes.
  • The approach holds potential for delivering highly potent drugs and treating challenging cancer phenotypes, including multidrug resistance.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer10:46

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer

Published on: September 13, 2022

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: